first one is from dan and gilead. i would like to maybe have you say a few words as two, number one, about remdesivir to start off with, and also the contributions be made by your company. we very much appreciate it. mr. o'day: thank you very much, mr. president. thank you to the vice president for the collaboration. let me start by saying on behalf overall the colleagues at gilead we would like to thank all the , collaborators who have brought remdesivir to this point. that includes the n.i.h., dr. fauci, and- commissioner hahn, and many more people that have been a part of this to bring this to where we are today. and in fact, the thanks go to the patients and caregivers who participated in these clinical trials. i am privileged to work with a group of amazing scientists at gilead who for decades, have been working on antivirals and were poised to put remdesivir immediately into clinical trials will resolve covid-19 circulating. so i am really proud of the colleagues in gilead. what i would like to say is on behalf

of gilead. we know what that is because he's been in the news, and great america company that's done incredible work on hiv and hepatitis c. and i hear that is what is happening with hepatitis, the great medical story, the great medical stories that we have been hearing about. that is. either way for the fda for remdesivir. you know what that is because that's been the hot thing in the papers and in the media for little while. an important treatment for hospitalized corona patients and something i spoke with dr. kohn, dr. fauci come i spoke with deborah about it. it is really a really promising situation. we have been doing work with the teams and the fda, nih, gilead for spearheading this private public partnership to make this happen quickly. so today, we are going to be -- i will let dan do it, but i will let dan tell us what he's doing to make a contribution to really people that are not doing well. people that are sick. people that have this horrible plague set into our country. and that we

so i'm really proud of the colleagues back at gilead. what i'd like to say is that on behalf of gilead, to the president's point, we feel a tremendous responsibility. we're humbled by this being an important first step for patients, for hospitalized patients. we want to make sure nothing gets in the way of these patients getting the medicine, so we made a decision to donate about 1.5 million vials of remdesivir. we will be working with the government to determine how best to distribute that, within the united states. we will be working very closely to get that to patients, working with fema, working with other parts of the government to make sure that we get that to the patients in need as quickly as possible, because there are patients out there that can benefit from this medicine today that are hospitalized, and we don't want any time to waste for that. we're also fully committed to continuing to expand the supply of this medicine. we started investing in this back in january, as soon as we became aware of the coronavirus. this is a lo

i'm proud of the colleagues at gilead. to say on behalf of president's point, this is an important first step nd wants to make sure nothing gets in the way of the patients getting the medicine. donating 1.5 vials of remdesivir. we'll be working with the government to determine how best to distribute that within the united states. we'll be working very closely to working to patients with fema, working with other parts of the government to make that to the get patients in need as quickly as possible. there are patients out there benefit from this medicine today that are hospitalized and we don't want any time to waste for that. fully committed to continued to expand the supply of this medicine. e started investing in this back in january as soon as we became aware of the coronavirus. is a long time to manufacture. it used to be 12 months. it's now six months. scientists have brought that down. as we get into the second half haveis year, we're able to many more supplies available to patients and we're fully committed to worki

we'll see you with gilead. becky?ut with results the current quarter results on this company is not going to be as closely watched they came in with a loss of 14 cents a share. street was looking for them to earn nothing, flat, flat, flat all the way across that loss of 14 cents include charges that total up to 67 cents for a non-cash valuation for lower commodity prices and asset impairments. if you strip that out, it's a gain of 53 cents again, i don't know where the street comes down on this or if that matters the bigger news coming out of the company today is they are cutting cap-ex by 33%. they are cutting their cash operating by 15% earlier in the week we learned that exxon would be maintaining its dividend of 87 cents a share. this is a playbook we heard it from chef rorch vroo michael wirth. andrew >> thanks, becky when we return, the ceo of gilead sciences is goi tjongo in us to talk all about it. stay tuned we're back after this. >>> gilead, maker of experimental coronavirus remdesivir it spent $50 million o

remdmdesivir is owned by gilead.iel stunned to hear o'day, the ceo repeat on your show, that t he will do his best to make gilelead available to eveveryone around ththe w worldd that h he had donatated a large numbmber of treatatments to t te united states. because g gilead's track recordn dedeliveng accccess to m medici, not jusust in thehe u.s. bubut elsesewhere, h has been horribl. the trump admininistration has coincidentally suing gilead for the unauthororized use of u.s. gogovernment patentsts f from tc --t are used in drugs thahat thdrdrug is what t many can tak, preventitiveeasure against hiv and aids. it costs $2525 a month to take n india. the e price of the u.s.s. is $1, which obviously acts as a deterrent t to find that drug ad thereforore constitutes a public healalth hazarard. the track record in brazil has been equally abysmal. they b brought to market in 201a thahat is the first ever treatment designed against hepatitis c, which is a debilitating a and fatalal disee that affects many y peop in middle

gilead says it is too early.n is telling investors to navigates as it the hardest time it is ever faced. it's all profit shrink. it is boosting spending to keep operations running smoothly during the pandemic. apple did not provide a forecast for the first time in more than a decade sparking concern that performance will suffer later this year. sending shares down. 1%pite the giant reporting a rise in quarterly revenue. and retail sales head to a new record. global news, 24 hours a day, on air and on quicktake by bloomberg, powered by more than 2700 journalists and analysts in over 120 countries. coming up, past the peak. boris johnson says the u.k. is through the worst of the outbreak and promises a lockdown exit plan. we discussed the outlook for the u.k. and the global lockdown next. this is bloomberg. ♪ ♪ let us start with antivirals. fight thehe drive to virus in your body. there was a recent promising report from a trial of gilead the company says ed helped patients recover faster from standard care. presid

gilead said it was too early to discuss a potential outlook. the first 1.5 million vaials of the drug. they say they plan a sustainable model for patients and shareholders. global news 24 hours a day, on air and on quicktake by bloomberg, powered by more than 2700 journalists and analysts in more than 120 countries. let's talk tech now. u.s. giant amazon, apple, and twitter have taken a hit from the coronavirus pandemic. says theceo jeff bezos online retailer may incur a loss in the current quarter to keep logistics running smoothly. apple has skipped out on giving a forecast for the first time in more than a decade as it reported quarterly revenues that grew just 1%. ceo tim cook says the firm saw a pickup in april, and the virus wreaked havoc on twitter's source of revenue, advertising. sales rose there just 3% in the first quarter, the smallest increase in more than two years. joining us is amanda lyons. thanks for joining us. let's talk about amazon first. i think i, like a lot of people, have been practically living off of amazon shopping

the president says gilead is receiving it out of the head counts.sident called the gilead ceo an important first step and is donating 1 million viral's of the drug as well, remdesivir. dr. peter, you are working on a vaccine yourself. thank you for coming back here. i'm reading the headlines, what is your reaction based on that information? >> this might be the second new treatment that seems to have some effect for covid-19. the first one was the plasma convalescent autobody, that is underway in multiple medical centers, even though we are still waiting for additional data, but this is the first small molecule drug that seems to have some benefits. so dr. fauci came out yesterday and said it looks like it is shortening the length of hospitalization and intubation required from 15 to 11 days, a 13% decrease. we have this funny result out of china that does not find the same thing. so we have to figure out what the chinese do differently from what we did and why they had a different result. i'm one of the things about the antiviral drugs and the anti

. >> i'm pleased to announce that gilead has an e-mail from the fda from remdesivir in u.s.is because that's been a hot thing in the papers and in the media for the last little while. liz: a major announcement from the president on gilead science remdesivir, remember we reported to you first that china back in january was trying to corner the patent on remdesivir. the fda greenlighted it looking like it is successful in treating covid-19. let's bring in our next guest fox news military analyst retired army colonel. this is the success story, optimism, gilead sciences says it can produce 140,000 of remdesivir by the end of may. and rise to a million doses by the end of 2020. they're talking several million doses by next year, were moving on this what is your take. >> it's great news. very happy, were fighting this thing every day, frontline people are doing an amazing job, everybody, it's one of those things were naturally very good news, it seems to me, obviously were a ways away from normalcy. will still be on the site for a while. liz: yeah i hear you. also a hundred natio

gilead science stock down 4.6%.hile as companies like gilead work to help flatten the virus curve, charlie gasparino is joining us right now to tackle flattening the economic curve. we're bringing in adam cohen, the ceo of a technology company that helps financial simplify small business loans. adam, charlie, welcome. and, you know, adam, we're about to run out of the ppp money, the second tranche of it, how do you do what you do to help sort of simplify the situation? >> well, we use ai to ensure safety and soundness and it's really a banking term. the banks are up against an incredible challenge i think is a monumental challenge in that they don't really have the capacity from the standpoint of human labor to on board new customers, and we've seen banks focus on their existing customer base and be criticized for it. our technology, what we do is we leverage ai to very quickly and efficiently ensure that banks are protected from fraud, terrorism, as they on board new customers. so what would normally take 14 days f

the university of o chicago encouraging note on the gilead study then confirmation from the stud y atl. >> scott gottlieb will be joining us later in the show take a quick break 12 minutes left in the session down 3%. we'll be back in a couple of minutes. and... let's get started. (music fades in) hey! -hi! ♪ ♪ ♪ ♪ you should be mad your neighbor always wants to hang out. and you should be mad your smart fridge is unnecessarily complicated. make ice. making ice. but you're not mad because you have e*trade which isn't complicated. their tools make trading quicker and simpler so you can take on the markets with confidence. don't get mad get e*trade and start trading commission free today. >>> cnbc's senior market commentator mike is here to break down the trading day welcome, keith let's start with the broader market fueled in part by worry that the white house could impose new r tariffs on china larry kudlow stressing that china should be held account bable for not doing enough to contain coronavirus and the pandemic and discuss whether additional tariff are in fact on the b table. >>

the first and only drug shown to work against covid-19 in a rigorous clinical trial, made by gilead. preliminary results show it shortens a patient's hospital stay by about four days. >> our task force will work closely with gilead to make sure those are distributed to hospitals. but there's a problem. gilead said there's only enough remdesivir for 200,000 patients worldwide, not nearly enough. >> an infectious disease specialist at the university of california, san francisco, was happy last week when the u.s. food and drug administration authorized the use of remdesivir for covid-19. >> i think there was excitement and then there was sadness and disappointment. >> why do you feel sad or disappointed? >> it means that more patients are potentially going to do badly. time is of the essence when you're talking about treating a virus. >> so doctors have to choose which of their patients will get remdesivir. >> we're in a tough spot. >> they're kind of asking you to play god. who gets the medicine and who doesn't. >> it's been challenging. >> i do believe that people who merit it are not

that designation expand's doctor's ability to use foster city-based gilead remdesivir on hospitalized patients with the most severe cases. earlier this week, a large study showed patients who received the medicine from gilead sciences were discharged four days earlier than those given the placebo. the company's ceo met with the president today, in the oval office. >> we saw the incredible human need, and we said in the event that this is successful, we have to plan for success and that's just the way we operate. i'm proud to work for a company that takes such a decision. >> gilead is donating its entire current supply of the drug, enough to treat 140,000 patients. it plans to manufacture a million treatments by the end of this year. >>> the owner of a vacaville barbershop reopened his doors this morning despite the risk of a citation. the shutdown order he believes is unamerican and unconstitutional and expects to be cited by the police but in the meantime, he is going to work. the mayor and other barbers who work in the shop were booked solid today. the mayor says not only are the ba

on the s&p and it didn't pull back as much either and we had the headlines and whether they be the gilead headlines and we had abbott labs and we've had different phases of treatment, testing and ultimately vaccine that have given the market hope for the last six weeks that either way is not going to be an immediate result and what i think the market has to come to grips with is this balance between what's going to be a staged recovery for people going back to work, even if we had the vaccine tomorrow through phase three with a bow on it so i think if you look at what the market did in the last hour of trading and it lost 30 s&p points and the trades that had been essentially not working for a couple of days which were the growth trades and the mega-cap check trades and the pristine balance sheet trades and those were ones that were more defensive into the close, and the markets will be in this range and the bears will point out to say hey, look, both technicals are around 2950 and the fundamentals three quarters of the we through earnings season don't get you excited like walmart in the

thanks for your time >> robyn of suntrust >> what do you make of gilead? >> she stuck to her guns with the stock call and it rallied to 85 and now here we are 72 or so, so that was a great call by them if nothing else you have something to trade against with $70 being the floor. countless times they're a victim of their own success and when you talk about what they did in the hepatitis world and i don't think you can bet the ranch on remdesivir it's a trading stock here and you own it at 70 bucks we've said that moderna in this world of covid-19 and that's proven to be correct. >> as guy said, hiv, the things that are slowly diminishing and it's just not enough and the balance sheet is fantastic and the business is solid and you don't own it for remdesivir and i don't think you own any of these companies for a vaccine. as we've heard between the economics and the long term forecasting which is very challenging and obviously the social factor. so i think gilead is neutral here and their core business is solid with a core pipeline that is diminishing so you

us. >>> welcome back after seeing positive results around its remdesivir drug, new comments from gilead about getting the drug out to as many people as fast as possible getting to those top headlines with frank holland >> gilead said it will work with international partners to produce remdesivir next year they expect to produce 140,000 rounds of the 10-day treatment by the end of may and anticipate it can make a million by the end of the year. amgen plans to test its drug otezla as well >> boeing raised $25 billion the number that says it will avoid taking government aid. the capital raised is the sixth largest bond offering of all time wells fargo, one of the largest home lenders says it will no longer accept applications for home equity lines of credit. chase also said it was dropping lines of credit and tightening conditions for which it will accept new mortgages >> on deck, would you buy a new car right now? we'll speak to the ceo of one of the largest car dealership chains and get his idea on the economic crisis. >> announcer: today's big number 12.7%. that is how much the s&p 500

gilead's ceo says the foster city company will start moving remedesavir earlier this week. the drug received emergency authorization from the food and drug administration on friday as a treatment for the coronavirus. gilead's clinical tests showed patients recovering in about 11 days, four days faster than those who got a placebo. the company plans on shipping to cities that are most vulnerable and have highest need. gilead donated 1.5 million to the government. >>> states are following their own paths as they start to reopen businesses and they go back to work. others are ramping up their efforts to get more protective equipment and increase testing. abc7 news reporter andrew dembert has the story. >> as some americans continue to voice their frustration over stay at home orders, across the country, some states have begun to reopen parks, streets and businesses. mark dewine announcing a phased reopening of his state. retail businesses can reopen on may 11th. and this morning on abc7 ne ini7 this week, he explained why he rescinded the face mask order. >> it was a bridge to

. >>> foster city-based gilead said its drug remdesevir is expected to arrive in hospitals this week. it follows a recent study led by the national institute of health that found the drug shortened recovery time for some coronavirus patients by four days. gilead ceo said it's ready to send its entire supply of the drug by this week. >> we are firmly focused on getting this medicine to the most urgent patients around the country here in the united states. and we intend to get that to patients in the early part of this next week or beginning to work with the government, which will determine which cities are most vulnerable and where the patients are that need this medicine. >> gilead said its supplies can treat up to 200,000 patients. >>> look at this story. this is new this morning. an act of kindness to help out our health care workers. an anonymous donor in santa cruz is gifting the dominican health hospital $1 million for its staff members so they can get extra bonuses. according to the associated press all full-time workers will each get $800 bonus this month. part-time worker gets

. >> john: in the oval office today, president trump welcoming gilead, pharmaceuticals. effective at treating coronavirus. at the today granting an emergency use authorization to make it more widely available. is >> it's a very promising situation. we've been doing work with the teams at the fda, and gilead for spearheading this private partnership to make this happen very quickly. >> gilead ceo saying he stomach his company will donate a hundred million miles so more patients can have access to the drug. >> we don't want any time to waste. we are also fully committed to continue to expand the supply of this medicine. >> in her first white house briefing, doubling down on the president's assertion yesterday that there is evidence to show the source of the pandemic was of urology lab in china. >> they're suggesting it could be in the wuhan lab report. >> president trump still saying it they might let. they took a swan dive today after the president suggested punishment could come. some say at this point, there is no serious consideration of slapping marked taxes on chines

gilead's ceo announcing the company will donate 1.5 million vial ares of the drug and help -- vials ofents in create a call need. and explosive new developments in the case against the

of gilead, which makes remedesavir. i'm norah o'donnell in washington. stay safe this weekend.monday. and good night. captioning sponsored by cbs captioned by media access group at wgbh access.wgbh.org when you think of a bank, you think of people in a place. but when you have the chase mobile app, your bank can be virtually any place. so, when you get a check... you can deposit it from here. and you can see your transactions and check your balance from here. you can save for an emergency from here. or pay bills from here. so when someone asks you, "where's your bank?" you can tell them: here's my bank. or here's my bank. or, here's my bank. because if you download and use the chase mobile app, your bank is virtually any place. visit chase.com/mobile. >>> a day packed with bay area protest, what happened when one group tried taking over a vacant home? we are there live with their message. >> what we would say is taking over house isn't the criminal activity. >> i want to know why or what the science is behind closing the beaches in orange county but not the beaches in san diego

gilead science will join us. and we'll look at the fallout as the number of jobless americans jumped to more than 30 million. we'll talk with rafs raphael bostic, and the c.e.o. of american airlines. all that and more is just ahead on "face the nation." ♪ >> brennan: welcome to "face the nation." as we turn the page to a new month, americans continue to struggle emotionally, financially, and with just trying to plan ahead. in most cases, there are few clear answers to our many questions. we will continue to seek them for you. our coverage begins today with cbs news stma a >>orter:n america's covid siege, askasks brasion were morph into rage. they argued, our oxygen-starved economy neats a ventilator. with 30 million jobs lost, millions of people are running low on something, food, toilet paper, patience, and especially money. you'll probably notice more stores reopen. 38 states have already eased restrictions, and six more will follow suit tomorrow and tuesday. >> if we hear minimal reports of knuckle-head behavi

gilead says there's only enough remdesivir for 200,000 patients at most worldwide. not nearly enough. dr. peter chin-hong, an infectious disease specialist at the university of california san francisco was happy last week when the u.s. food and drug administration authorized it for covid-19. >> i think there was that excitement then there was sadness and disappointment. >> why do you feel sad or disappointed? >> every day you don't get a drug it means more patients are potentially going to do badly because time is of the essence when you're talking about treating a virus. >> reporter: so doctors have to choose which of their patients will get remdesivir. >> we're in a tough spot. >> reporter: they're asking you to play god who gets the medicine and who doesn't. >> it's been challenging. i do believe that people who merit it aren't going to get it because we don't have enough. >> reporter: doctors want to give to it their patients who could benefit most but they don't necessarily know who those patients are since the study on remdesivir still hasn't been published. t

is, one company partners with gilead, i was just curious -- gov. justice: i can answer the tost question and i may have defer the second question to somebody else. i think bernie does a fabulous job and he's looking out for our athletes and our instructors and all that kind of stuff. sure they will have guidelines and they will restrict workouts to so many kids at a time or whatever like that. we will work with them under guidelines and everything that they do great work. they will do the right thing there and protect our kids. can't say enough, they do really good work. the second part of the question, if you want to try that one more time. mylan is one of the companies that partners with gilead to make remdesivir. i can address that one if you would like. gov. justice: go ahead. dr. slemp: it's a great question, i actually don't know. gilead donated the supplies to the federal government and it has come directly from hhs. so we will have to find out more about the manufacturing. mark.es would go to >> good afternoon. i know that workforce west ha

talk to us how promising this deal with gilead could be. >> so gilead last week you'll remember was inse it's experimental drug remdesivir received some positive early trial results and also received usda approval for early use. now they're looking for for trial results to come through but to the supplyside of the equation. and we learned that gilead is in discussion with a number of different chemical and pharmaceutical companies around the world to ensure that there is ample supply. they are negotiating long-term volunteer licenses with drug makers in india and pakistan to ensure that they can produce remdesivir for developing countries and then also around europe and asia. so a significant -- significant discussions for sure. one other sector we've been closely following, the u.s. meat sector. the u.s. is facing meat shortages as processing plants have been closed due to the pandemic and the spread of coronavirus there. one country, though, that has continued to import u.s. pork and beef is china. the u.s. exported nearly 96,000 tons of pork to china in march, that's the second high

made by the company gilead, preliminary results show it shortens the patient's hospital stay by aboutur days. >> our task force will be working closely with gilead to make sure that those medicines starting on monday are distributed to hospitals where patients are struggling. >> reporter: but there's a problem. gilead says there's only enough remdesivir for 200,000 patients at most worldwide, not nearly enough. dr. peter chin hong an infectious disease specialist at the university of california san francisco was happy last week when the u.s. food and drug administration authorized the use of remdesivir for covid-19. >> i think there was that excitement, and then there was sadness and disappointment. >> reporter: why do you feel sad or disappointed? >> every day you don't get a drug. it means more patients are potentially going to do badly because time is of the essence when you're talking about treating a virus. >> reporter: so doctors have to choose which of their patients will get remdesivir. >> we're in a tough spot. >> reporter: they're kind of asking to you play god, who gets the

gilead, the foster city company that makes the drug says it will donate more than 1 million viles with more on the way. that is enough to treat about 140,000 people. today, gilead's ceo will be on "face the nation." >>> this doesn't cure the disease, it doesn't prevent it, but it takes four days off the recovery time. that is good, because it could help. i will ask about getting this scaled up. what it could cost and what future perhaps combinations drugs might be more effective. >>> if you're interested, you can see that interview with gilead's ceo on "face the nation" coming up at 8:30 this morning right here on kpix 5. >>> coming up, a nonprofit raises millions of the dollars to help bay area restaurants and front line workers at the same time. >> plus, a big send off for a northern california doctor headed to help fleet coronavirus patients >>> a nonprofit is providing front line workers with tasty meals and it is keeping local restaurants afloat as well. one of off their plates, they are raising money to give directly to a local restaurant and then that restaurant cooks food for h

gilead and roche teaming up for a late stage trial in the battle against covid-19.ng us is bloomberg pharma reporter robert landreth. we have seen about a half dozen or more partnerships at this point. abert: yes, this is partnership looking at two different drugs that would work against hospitalized patients with severe cases of covid in two different ways. remdesivir, the gilead drug that everyone has heard about, and , inviral given by infusion the trial sponsored by the national institute of health, people got out of the hospital four days earlier. the roche drug, what happens with very sick patients in late stages, it is believed that the inflammation, the reaction to the virus by the immune system, kind of gets out of control. that may contribute to some of the deaths from the coronavirus. this rochedrug -- drug is an anti-inflammatory , so it would calm down the immune system in the late stages of the disease. it is already being tested, but now they are going to combine it with the antiviral drug from gilead that got emergency authorization a few weeks ago i

still, gilead has proven to be a company with strength here. biotech has become the forefront of the stock sentiment of where we are with this pandemic. chips a concern today after reports that the trump administration is in talks with various chip companies about manufacturing more chips in the united states versus asia to improve reliance in the supply chain. taylor: this is a story about turnarounds. slowly, throughout the day, it started to inch up higher and higher. this pandemic has created concerns about the supply chain in asia. over the weekend, we did hear reports that they were looking at companies like intel, taiwan semiconductor, about making them open up plants in the u.s. negative territory, then closing in near positive territory, saying it might not be a thing in the near term. steeple analysts said that the report is not surprising but they don't think any report will nearminent and there is no financial impact. analysts at citigroup said in expansion as possible for bringing manufacturing plants from those chipmakers in the u

will get less than half of the 1.5 million vials that gilead is donating worldwide.al health officials say there is enough to treat a 8000 patients, but many more would qualify for it if the drug were available. the chinese city where the coronavirus pandemic started has reported its first new infection since april 8. that is when wuhan ended at 76 day lockdown. new cases were found and people were already under quarantine. china is slowly reopening its economy. the european central bank up. the european commission threatened twice to sue germany. the issue, a ruling by the german constitutional court that challenge the ecb's monetary authority. the european commission says the final word come from luxembourg. global news 24 hours a day, on air and on quicktake by bloomberg, powered by more than 2700 journalists and analysts in over 120 countries. i am mark crumpton. this is bloomberg. guy? guy: thanks very much, indeed. we are getting details from new york. 160 one new virus debts being reported. that is the lowest number since march 26, but it looks like the lockdo

. >>> foster city-based gilead says its drug remdesivir is expected to go to hospitals this week. approved the drug for emergency use on friday follows a recent study by the institute of health that found the drug shortens recovery time for some coronavirus patients by four days. gilead ceo said it's ready to send its entire supply of the drug by this week. >> we are firmly focused on getting this medicine to the most urgent patients around the country here in the united states. and we intend to get that to patients in the early part of next week and beginning to work with the government, which will determine which cities are most vulnerable and where the patients are that need this medicine. >> gilead said its supply is enough to treat roughly up to 200,000 patients. >>> and new this morning, an act of extreme generosity and kindness to help out all our health care workers. an anonymous donor has just given an enormous check to dominican in santa cruz. this is a million dollars that will help our front line workers. according to the ap, all that money is going to be divided up am

gilead expects to manufacture more than 1,000,000 1/2 doses by the end of the month. we will have much more on this developing story coming up at 6:00. >>> one day after governor newsom decided not to close bay area beaches, there are now some restrictions in santa cruz. >> reporter: access to the coast of california's beaches has been come become one of the thorniest issues during the stay-at-home order and its because californians believe the beaches belong to everyone. we shot this video short time ago that shows sheriff's deputies and police officers with the santa cruz police department ticketing some people at the beach at cal beach here near the boardwalk. health officials say this is a nightmare scenario to have people coming from all over the area, congregating at the beach and then returning home, possibly with the virus in tow. >> i think we should be compassionate, reasonable and fair about beach access. >> reporter: santa cruz county is closing all of its beaches between 11 am and 5 pm every day, a policy designed specifically to discourage day trips to t

remdesivir is made by the american firm gilead sciences. the company published the results of the study in the new england journal of medicine. 200 patients were given remdesivir for five days. within two weeks of the start, 60% of them had been discharged. almost 200 other patients had received remdesiver for ten days. within two weeks of the start, more than 50% of them had been discharged. the company also reported the median number of days patients were in the hospital. for those on the five-day course of remdesivir, it was seven for those on the ten-day course, it was eight. gilead sciences concludes there's no big difference in outcomes. still the company says the drug's actual effectiveness is hard to judge because the trial did not include a placebo. remdesivir was originally developed to treat ebola. earlier this month japan became the first country to approve it for covid-19. the united states has approved it for emergency use. clinical trials are underway in a number of countries to determine how safe and effective it is for peop

gilead donating its supply of the drug remdesivir. we'll talk all about it next. >>> as we head to a break, take a look at the biggest premarket decliners in the s&p 500 right back after a short break >>> good morning u.s. equity futures holding back in premarket trade the dow down 244 points. s&p 500 down 23 and change nasdaq off 51. the energy complex is weak after -- actually, rebounding last week almost back to 20 on wti. this morning back down almost 8%, to $18.23. >> meantime, just days after the fda approved emergency use of gilead's use of remdesivir, the company says it's donating the entire supply to the government. let's get to meg with more on that story meg? >> good morning, andrew. they say that the distribution of that drug will begin as soon as this week we also learned, though, in the fda's letter to gilead granting that emergency thoeshgs use for remdesivir, the government said it would control the distribution of the drug in is surprising a lot of people in the biotechnology world an analyst who has covered the indu

right now, we do have gilead science is down about half a percent after seeing quite a run -up over the past couple of weeks and eli lilly is moving higher by half a percent. granted we are only eight days into may, but spirit airlines report they are seeing an up-tick in demand for the month, compared to april , when we know the bottom fell out of the entire airline industry after the coronavirus virtually shutdown the airlines the comeback is welcome but it is slow, folks. jet blue has slashed its daily number of flights from 1,000 to 100 and today though it's getting a nice move up 9.6%, spirit pulling back today, 1.5%. we have a good news/bad news final hour of trade for disney. tickets for shanghai disneyland, may openings sold out in just minute, even as chinese authorities limited the park's capacity. the bad news? widely-respected media analyst rich greenfield advised clients to sell the stock saying until the world feels comfortable and safe from the virus, disney's earnings are "fundamentally impaired." walt disney though is up 2.6% so we know which side of this the investors

reporters and reuters who are in an event with the president, the president has just announced that gileadthe company that has been developing and done the trials on the coronavirus, potential coronavirus treatment remdesivir, that gilead has now received the fda approval for the emergency authorization from the fda to begin using this treatment. dr. fauci had said this was likely to be coming soon and would happen quickly. the president announcing that it now has happened. and president trump also announcing that the gilead ceo is going to be donating 1 million doses of remdesivir. much more on that to come. >>> in talking about the impact of coronavirus on patients of all ages, we have top officials who are looking for treatment and for a vaccine for the coronavirus, remdesivir being one of them. as they look for these fixes and for a vaccine, there is a scary new complication emerging in patients not considered the most vulnerable. a troubling jump in sudden strokes among covid patients in their 30s and 40s who are not otherwise terribly ill. one of the doctors who has been treating pat

now, the studies, conducted by gilead, have found that the drug could improve or shorten recovery time for people who are suffering the most severe effects of coronavirus. let's bring in emery university medical school, the doctor there, anis meta. good morning to you. >> good morning. >> let me start here, those four days -- we can put up the findings of your study. it reduced the median recovery time by four days, 11 days down from 15. of course nobody wants to be in the hospital, everybody wants to recover and go home. what do those four days buy you? a less likelihood of permanent injury or scarring? what's saved by those four days? >> for the last two months or so i've been taken care, with my colleagues, of several patients with covid-19, some have mild cases but many have more severe cases and end up in the hospital for a long period of time. at emery we were honored to be part of this clinical trial to look at the medicine called remedesivir to see if it would improve the outcome of our patients with covid-19. we're still waiting for the final data to come out in a few weeks bu

we're seeing gilead, remdesivir may work in a cocktail with other drugs.ead moving to make generic -- in other words they're seeing good news on cures and vaccine front. gilead is working to make a generic version of it. roche's antibody test, 100% accurate. convalescent plasma treatments working. johns hopkins, mayo clinic finding that as well. we're seeing good news on that front. are you seeing that too, you know, there is positive news there? >> look, there are a lot of very smart doctors and researchers in this country and the world and they have been learning as we go along, have been improving the way they treat people who have coronavirus. i think one of the most heart rending things we saw when reports came out several, several weeks ago about how, how use of ventilators was not effective in many cases, physically repositioning the patient was much more helpful. it was tragic, you thought people who had been treated before they came upon that. so, treatments are improving every day. when you, when you look at this, this flattened curve, it is actu

i am pleased to announce that gilead now has a eua from the fda for remdesivir, you know what that isn the papers and media for the last little while. an important treatment for hospitalised coronavirus patients, and something i spoke with dr khan and dr fauci, i spoke with deborah about it. it is really a very promising situation. we have been doing work with the teams at the fda, nih and gilead for spearheadhing this private—public partnership to make this happen very quickly. our north america correspondent david willis is following the story. this drug is said to be helping patients suffering coronavirus to recover faster. there was a trial conducted involving about a thousand patients and it showed that those who took the drug recovered, normally it would be about 15 days, pared down to 11 days. that's a 31% difference and it's seen by medical experts here as potentially very significant if for no other reason than the fact that it suggests to them that a drug is capable of blocking this virus. now, it's a modest breakthrough but it is all we have at the moment. it's not a cure,

foster city based gilead sciences say its drug is showing promising results in clinical trials.onight gilead says it could produce several million rounds of remdesivir next year and within the coming days, the fda is expected to issue an emergency use order for the drug. that will allow it to be given to covid-19 patients even though it doesn't have official approval yet. >> we are looking next at whether or not now we have one really good drug, whether or not if we combine two drugs that work in different ways, can we attack this disease even better? >> preliminary results from a national institutes of health study show the median recovery time for patients who took remdesivir was 11 days compared to 15 days for those who took the placebo. >>> workers are preparing to go on strike at some of america's largest companies tomorrow, may 1st, mayday. they say they are working in unsafe conditions. employees from amazon, whole foods, walmart, target, fedex, and others will protest tomorrow and are asking customers to boycott those businesses. >>> essential workers who need help findi

has -- >> gilead gets

i am pleased to announce that gilead now has a eua from the fda for remdesivir, you know what that ist has been a hot thing also in the papers and media for the last little while. an important treatment for hospitalised coronavirus patients, and something i spoke with the doctors and deborah about it. it is really a very promising situation. we have been doing work with the teams at the fda, nih and gilead for spearheadhing this private—public partnership to make this happen very quickly. we will be getting more from oui’ correspondence we will be getting more from our correspondence david willis shortly. there are growing reports from the us that the trump administration is formulating a plan to punish china on multiple fronts for the coronavirus pandemic, further damaging a relationship already on a steep downward slide. with an election just six months away, some of the president's critics believe a campaign strategy of blaming beijing is emerging, to divert attention from president trump's handling of the crisis. danny russel is the vice—president at the asia society policy instit

gilead and nih studies show that 30% of the patients who take the drug improve.e larsen has the details. >> we want to thank all the collaborators that have brought remdesivir to this point. >> reporter: the ceo of gilead, daniel o'day in the oval office on friday, the bay's pharmaceutical company developed remdesivir, the first drug approved for emergency use. >> it works by preventing the virus from making more copies of itself. >> reporter: aruna subramanina is the co-lead on gilead's remdesivir study. more patients can take advantage of the current drug supply. subramanian worked on aids clinical trials and explained why remdesivir wirks does not cure covid-19, is a critical milestone. >> our first drug was htc in hiv and then we added more drugs to give an antiviral cocktail that really worked very, very well. >> what they'll now do is use remdesivir as the new placebo or standard of care and fold in other drugs along the way. >> reporter: dr. neera ahuja also works at stanford. she was the primary investigator on a larger remdesivir study which showed patie